Core Insights - Esperion's bempedoic acid has been recognized as a first-line therapy for lowering LDL-C in patients with peripheral artery disease (PAD) and diabetes, as highlighted in the 2025 American College of Cardiology (ACC) Scientific Statement [1][4] Group 1: Company Positioning - Esperion emphasizes the significance of aggressive LDL-C lowering in high-risk populations, reinforcing bempedoic acid's role in reducing cardiovascular and limb risks [2] - The company anticipates that bempedoic acid will be included in the upcoming U.S. dyslipidemia treatment guidelines from ACC/American Heart Association (AHA) in early 2026, following its endorsement in European guidelines [3] Group 2: Clinical Evidence - The ACC scientific statement incorporates data from the 2024 AHA Scientific Sessions, which demonstrated that bempedoic acid reduced major adverse limb events (MALE) by 36% compared to placebo in patients with pre-existing PAD [5] - Bempedoic acid is positioned as a safe and well-tolerated oral option for lowering LDL-C and reducing the risk of MALE in patients with PAD [5] Group 3: Product Indications - Bempedoic acid, as part of NEXLIZET and NEXLETOL, is indicated for reducing the risk of major adverse cardiovascular events in adults unable to take statin therapy [8] - NEXLIZET and NEXLETOL are also indicated for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) [8]